TRT vs Enclomiphene: Which Is Right for You?

What Is TRT and How Does It Work?

Testosterone replacement therapy delivers synthetic testosterone into the body through an injection, gel, patch, or implanted pellet. The added hormone binds androgen receptors throughout muscle, bone, brain, and cardiovascular tissue, correcting the downstream effects of deficiency. Because the brain senses adequate circulating testosterone, it reduces gonadotropin-releasing hormone (GnRH) output, which in turn drops LH and FSH, and the testes stop producing both testosterone and sperm.

The Endocrine Society's 2018 Clinical Practice Guideline defines symptomatic male hypogonadism as a total testosterone below 300 ng/dL confirmed on two morning samples, combined with at least one symptom from a recognized cluster including reduced libido, fatigue, depressed mood, or loss of muscle mass [1]. Roughly 2.1% of men aged 40-79 meet that biochemical threshold in population data [2].

The most prescribed injectable forms in the United States are testosterone cypionate (half-life approximately 8 days) and testosterone enanthate (half-life approximately 4.5-5 days). Both are esterified versions of the same hormone; once cleaved in circulation, they release identical free testosterone [3]. The practical differences are covered in the cypionate-versus-enanthate section below.

Transdermal gels such as AndroGel 1.62% and Testim avoid the peak-and-trough swings of weekly injections, but daily application carries a small transfer risk to partners and children [4]. Subcutaneous pellets (Testopel) release testosterone over 3-6 months but require an in-office insertion procedure; dose adjustments are impossible until the pellets dissolve [5].

What Is Enclomiphene and How Does It Work?

Enclomiphene is the trans-isomer of clomiphene citrate, separated from its cis-isomer (zuclomiphene). Standard clomiphene (Clomid) contains roughly 38% enclomiphene and 62% zuclomiphene. Zuclomiphene has a longer half-life and accumulates in tissue over weeks, which is the source of most of the visual and mood side effects associated with generic clomiphene in men [6].

Enclomiphene acts as a selective estrogen receptor antagonist at the hypothalamus and pituitary. By blocking estrogen's negative feedback signal, it allows GnRH to pulse more freely, raising LH and FSH. Those gonadotropins then drive the testes to produce more testosterone and, crucially, to maintain spermatogenesis [7].

A Phase II randomized trial (N=124) published in the International Journal of Impotence Research found that 12.5 mg enclomiphene daily for 12 weeks raised mean total testosterone from 230 ng/dL to 419 ng/dL, while sperm concentrations remained stable or improved compared to baseline [8]. The testosterone cypionate arm in the same study produced higher peak T values but reduced sperm counts by more than 90% in most participants.

Androxal (Repros Therapeutics) received a complete response letter from the FDA in 2014 citing manufacturing concerns rather than efficacy data, so clinicians currently prescribe it off-label through compounding pharmacies [9]. That regulatory status matters for insurance coverage: most plans will not reimburse compounded enclomiphene.

TRT vs Enclomiphene: The Fertility Question

This is the single most important clinical fork in the road. TRT suppresses spermatogenesis. Full stop.

A prospective cohort study (N=72) in Fertility and Sterility found that 93% of men on intramuscular testosterone developed azoospermia or severe oligospermia within 6 months of starting therapy [10]. Recovery of sperm production after stopping TRT takes an average of 6-12 months, and in some men it may never return to pre-treatment levels [11].

Enclomiphene does the opposite. Because it stimulates endogenous LH and FSH, intratesticular testosterone remains high enough to support sperm maturation. A 26-week open-label study published in BJU International (N=40) showed a statistically significant rise in sperm concentration from 33 million/mL to 53 million/mL (P<0.01) in men taking 12.5-25 mg enclomiphene daily, alongside a mean total testosterone increase of 181 ng/dL [12].

The practical rule: any man who has not completed his family should discuss enclomiphene, or at minimum HCG co-administration with TRT, before starting exogenous testosterone [1]. The Endocrine Society guideline explicitly states that clinicians should "inform men who desire fertility that testosterone therapy impairs spermatogenesis" [1].

Comparing Testosterone Levels: TRT vs Enclomiphene

TRT produces higher and more controllable serum testosterone. An experienced clinician can titrate cypionate from 100 mg/week to 200 mg/week and predict, within roughly 150 ng/dL, where the patient will land. Gel formulations allow fine-grained daily adjustments.

Enclomiphene has a ceiling. The pituitary can only respond so much to disinhibition, and the testes have a finite Leydig cell capacity. Men with primary hypogonadism (testicular failure reflected by high LH and FSH at baseline) will get little or no response from enclomiphene because the problem is in the testes, not the feedback axis [13]. For those men, TRT is the only pharmacological option.

Secondary hypogonadism (low T with low or inappropriately normal LH/FSH) is where enclomiphene performs best. A 2019 randomized controlled trial in the Journal of Clinical Endocrinology and Metabolism (N=74) confirmed that enclomiphene 12.5 mg and 25 mg daily produced testosterone levels in the eugonadal range in secondary hypogonadal men over 3 months, with no significant change in hematocrit, PSA, or lipid panels compared to placebo [14].

The HealthRX clinical team uses a three-question framework for every new hypogonadism consult:

1. Is LH/FSH elevated (primary failure) or low/normal (secondary failure)?
2. Does the patient have active fertility goals within the next 24 months?
3. How quickly does the symptom burden need to be addressed?

If the answer to question 1 is primary failure, the conversation moves directly to TRT formulation selection. If secondary failure is confirmed and the answer to question 2 is yes, enclomiphene is the first-line recommendation. If the answer to question 3 is urgently (severe depression, significant muscle loss, markedly impaired quality of life), TRT typically delivers faster, larger symptom relief.

Testosterone Cypionate vs Enanthate: Practical Differences

Cypionate and enanthate are the two dominant injectable esters in the United States. The clinical distinctions are subtle but real.

Testosterone cypionate has an 8-carbon ester chain versus enanthate's 7-carbon chain. That single carbon adds roughly 1-2 days to the half-life: 8 days for cypionate versus 5-7 days for enanthate [3]. In practice, most men on weekly injections will not notice a meaningful hormonal difference between the two. Men who inject every two weeks (a less optimal but sometimes preferred schedule) may find cypionate produces slightly smoother levels toward the end of the interval.

Cost and availability differ. Testosterone cypionate is manufactured domestically in the US by multiple generic producers, making it consistently available and priced at roughly $30-60 for a 10 mL multi-dose vial. Enanthate is more common in European markets and can be harder to source through US retail pharmacies, occasionally requiring a compounding pharmacy [3].

Carrier oil matters for some patients. Cypionate formulations commonly use cottonseed oil, while enanthate preparations may use sesame or castor oil. Men with sesame allergies should confirm the carrier before their first injection [15]. Injection-site reactions, including post-injection pain and sterile abscess, are more closely linked to concentration and carrier oil than to the ester itself.

Neither formulation is clinically superior for testosterone delivery. The American Urological Association's 2022 hypogonadism guideline does not preferentially recommend one over the other [16].

Testosterone Cypionate vs Gel: Which Delivery Method Works Better?

Injectables and gels each have real advantages. The right choice depends on lifestyle, venipuncture comfort, and whether stable daily levels matter more than the convenience of a biweekly or weekly shot.

Testosterone gels produce flatter serum testosterone curves than weekly injectables. Daily application of AndroGel 1.62% (20.25-81 mg testosterone) maintains steady-state concentrations within a relatively narrow band, avoiding the supraphysiologic spike on injection day and the sub-optimal trough near the end of a weekly cycle [4]. A randomized crossover study in the Journal of Clinical Endocrinology and Metabolism (N=40) found that men on transdermal testosterone reported fewer mood fluctuations compared to those on weekly injections, though total testosterone AUC was comparable [17].

Gels carry a transfer risk that injectables do not. The FDA added a black-box warning to testosterone gel products in 2009 after reports of virilization in children exposed to treated skin [4]. Patients must wash their hands after application, cover the treated area with clothing, and shower before contact with children or female partners.

Injectables are more cost-effective and require no daily adherence. A 10 mL vial of testosterone cypionate at 200 mg/mL covers 20 weekly doses at 100 mg, costing less than $3 per dose at generic pricing. Gels cost considerably more out of pocket, often $200-$500 per month without insurance.

Subcutaneous self-injection of testosterone cypionate using a 27-gauge 0.5-inch needle has grown in popularity because it produces slower absorption and smoother levels than intramuscular injection, approximating the flat curve of a gel while retaining the cost advantage of injectables [18].

TRT vs Clomid (and Enclomiphene vs Clomid)

Generic clomiphene citrate (Clomid) has been used off-label for male hypogonadism for decades. It raises testosterone through the same mechanism as enclomiphene (pituitary disinhibition), but its zuclomiphene content produces more side effects.

A retrospective analysis of 86 men on clomiphene in the Journal of Urology found that 40% reported mood changes, 25% reported visual disturbances (blurring, afterimages), and 18% discontinued within 6 months [19]. Visual symptoms are attributed to zuclomiphene's prolonged tissue accumulation and its effects on retinal photoreceptors.

Enclomiphene, by isolating the active isomer, reduces those side effects substantially. A head-to-head pharmacokinetic study confirmed that zuclomiphene accumulates to detectable serum levels within 2 weeks of standard clomiphene use, whereas enclomiphene clears within 24-48 hours of each dose [6]. That rapid clearance is why enclomiphene causes fewer visual complaints and may be better tolerated long-term.

Both clomiphene and enclomiphene fail in primary hypogonadism. Both require intact pituitary and testicular function [13]. Both preserve fertility better than TRT. The key advantage of enclomiphene over generic clomiphene is the side-effect profile, not a substantially different efficacy ceiling.

TRT vs Natural Boosters

Supplements marketed as "natural testosterone boosters" include ashwagandha (KSM-66), zinc, vitamin D, D-aspartic acid, and tongkat ali, among many others. The evidence base is thin compared to TRT or enclomiphene.

A double-blind RCT published in Medicine (N=57) found that 600 mg KSM-66 ashwagandha daily for 8 weeks raised total testosterone by a mean of 96 ng/dL (from 630 to 726 ng/dL), which is a statistically significant but modest effect in men who were not frankly hypogonadal at baseline [20]. In a man starting at 220 ng/dL with symptomatic deficiency, a 96 ng/dL rise may not bring him into the normal range. TRT can reliably deliver 400-700 ng/dL of additional testosterone above baseline.

Vitamin D supplementation in deficient men raises testosterone marginally. A 12-month RCT (N=165) in Hormone and Metabolic Research found a mean testosterone increase of 65 ng/dL in the vitamin D group versus no significant change in placebo [21]. Again, meaningful in a borderline case, insufficient in true hypogonadism.

Natural boosters carry no suppression risk, no fertility risk, and no hematocrit elevation. They are appropriate for men with borderline-low testosterone (280-349 ng/dL), no significant symptoms, or men unwilling to commit to prescription therapy. For men with confirmed symptomatic hypogonadism below 300 ng/dL, supplements alone are unlikely to produce clinical resolution of symptoms.

Side Effects and Safety Monitoring

TRT side effects worth knowing:

Erythrocytosis (elevated hematocrit) is the most common dose-dependent adverse effect. Data from a prospective registry of 3,876 men on TRT found a hematocrit above 54% in 11.4% of participants, requiring dose reduction or phlebotomy [22]. The FDA recommends checking hematocrit before initiating therapy and at 3-6 months thereafter [9].

Testicular atrophy occurs because LH suppression removes the intratesticular testosterone signal that maintains Sertoli and Leydig cell activity. HCG (typically 500-1 to 000 IU subcutaneously two to three times per week) co-administered with TRT largely prevents this, while also preserving some residual fertility [1].

Estradiol elevation from testosterone aromatization may cause gynecomastia or fluid retention in susceptible men. An aromatase inhibitor (anastrozole 0.25-0.5 mg twice per week) is sometimes added when estradiol exceeds 40-50 pg/mL with symptoms, though routine use is not recommended by the Endocrine Society [1].

Enclomiphene side effects:

Enclomiphene is generally well-tolerated in reported studies. The most common adverse events in the Phase II trial were headache (12%), nausea (8%), and mood changes (6%), all of which resolved with dose reduction or discontinuation [8]. Estradiol may also rise on enclomiphene because higher endogenous testosterone is substrate for aromatization; monitoring estradiol at 6-8 weeks is advisable.

Because enclomiphene raises both LH and T endogenously, polycythemia risk appears lower than with exogenous TRT, though long-term registry data in men are not yet available.

Dosing Reference: Standard Starting Points

Testosterone cypionate: 100 mg intramuscularly or subcutaneously once per week (or 50 mg twice per week for smoother levels). Titrate based on mid-cycle trough testosterone at 6-8 weeks [1].

Testosterone enanthate: 100-200 mg intramuscularly once per week. Pharmacokinetic profile supports twice-weekly dosing (50-100 mg per injection) for tighter control [3].

AndroGel 1.62%: One pump (20.25 mg testosterone) applied to upper arms and shoulders each morning. Dose may be increased to two or four pumps based on 14-day post-initiation serum levels [4].

Enclomiphene citrate: 12.5 mg orally once daily for the first 4 weeks, with dose escalation to 25 mg daily if testosterone response is inadequate at 6-week follow-up. Doses above 25 mg/day have not consistently added benefit in published trials [8] [14].

Generic clomiphene (for comparison): 25-50 mg every other day or daily. Lower doses are preferred in men to reduce zuclomiphene accumulation [19].

Which Option Does HealthRX Clinicians Typically Start With?

For men with confirmed secondary hypogonadism and active fertility goals, enclomiphene 12.5 mg daily is the preferred first-line agent at HealthRX, with a 6-week check of total testosterone, LH, FSH, and estradiol.

For men who have completed their families and want the fastest, most reliable symptom resolution, testosterone cypionate 100 mg/week subcutaneous self-injection is the starting protocol, with HCG 500 IU three times per week added if testicular atrophy or future fertility preservation is a concern.

For men who object to injections and have no transfer-risk concerns, AndroGel 1.62% at two pumps (40.5 mg) daily is a reasonable alternative, with the understanding that absorption variability is higher than injectables.

Check total testosterone, free testosterone, hematocrit, PSA, and LH/FSH before any prescription is written. A baseline semen analysis is standard for any man under 45 who has not yet had children, regardless of which agent is selected.